ChengDu ShengNuo Biotec Co.,Ltd.

Equities

688117

CNE1000051M8

Pharmaceuticals

End-of-day quote Shanghai S.E. 03:30:00 28/06/2024 am IST 5-day change 1st Jan Change
24.54 CNY +4.87% Intraday chart for ChengDu ShengNuo Biotec Co.,Ltd. +6.19% -12.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sheng Nuo Biotec's Unit Gets Nod to Produce Posaconazole Injection MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cheng Du Sheng Nuo Biotec Completes US FDA Filing For Constipation Drug API MT
Biocells Biotechnology Co., Ltd. announced that it has received funding from ChengDu ShengNuo Biotec Co.,Ltd., Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd., Green Pine Capital Partners Co., Ltd. CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
ChengDu ShengNuo Biotec Co.,Ltd. cancelled the transaction announced on May 16, 2023 CI
Sheng Nuo Biotec's Unit Gets Nod to Amend Usage of Carbetocin Injection MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Three Cheng Du Sheng Nuo Biotec Execs to Divest Stakes MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
GermanLitho announced that it has received funding from Jingzhou Huaying Capital Venture Capital Management Partnership Enterprise (L.P.), ChengDu ShengNuo Biotec Co.,Ltd. CI
WNL Biomedtech announced that it has received funding from Huaying Capital, ChengDu ShengNuo Biotec Co.,Ltd. CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
ChengDu ShengNuo Biotec Co.,Ltd.(SHSE:688117) added to Shanghai Stock Exchange Composite Index CI
ChengDu ShengNuo Biotec Co.,Ltd.(SHSE:688117) added to Shanghai Stock Exchange A Share Index CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Meishan Huilong Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 50 million in funding from ChengDu ShengNuo Biotec Co.,Ltd. CI
Chart ChengDu ShengNuo Biotec Co.,Ltd.
More charts
ChengDu Sheng Nuo Biotec Co Ltd is a China-based company mainly engaged in the research and development of peptide active pharmaceutical ingredients (APIs) and preparation products. The Company's main business includes independent research and development, production and sales of peptide APIs and preparations, providing pharmaceutical research services for peptide innovative drugs, customized production services for peptide products and transfer services for peptide drug production technology for domestic and foreign pharmaceutical companies, providing original equipment manufacture processing of small molecule chemical drug levosimendan preparations and levosimendan API production, export and sales business. The Company's products target areas including immunity, digestive tract, antiviral, obstetrics and gynecology, diabetes, cardiovascular and cerebrovascular, rare diseases, orthopedics and others. The Company mainly conducts its business in domestic and foreign markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
24.54 CNY
Average target price
38 CNY
Spread / Average Target
+54.85%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688117 Stock
  4. News ChengDu ShengNuo Biotec Co.,Ltd.
  5. Cheng Du Sheng Nuo Biotec Completes US FDA Filing For Constipation Drug API